ClinicalTrials.gg
Not yet recruitingNCT06579846MEDSEC-CTA12Updated Sep 4, 2024

12-Month Efficacy of Exercise and Cytisinicline for Tobacco Abstinence

A Phase 4 interventional study of Cytisinicline and exercise and Cytisinicline in Smoking Cessation, sponsored by Maimónides Biomedical Research Institute of Córdoba. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-04.

Sponsored by Maimónides Biomedical Research Institute of Córdoba · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing cytisine in Smoking Cessation — 3 open to participants now, 5 under way, 1 of them phase 3. cytisine · Smoking Cessation.

Planned enrollment
12th of 22
150 · median 202
Started
2025
the only one that year
Phase 4
3 of 22
1 open now
Registered
20th of 22
by date
Lead sponsor
1 of 22
Maimónides Biomedical Research Institute of Córdoba

Among the 22 studies testing cytisine in Smoking Cessation, this one is the 12th largest by planned enrollment, is the only one that started in 2025, is one of 3 in phase 4, and was the 20th registered.

Smoking Cessation

1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

3 of the 22 studies testing cytisine in Smoking Cessation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cytisine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing cytisine in Smoking Cessation, or all of them as a file.
02

Study summary

Current scientific evidence demonstrates the relationship between good physical fitness and a lower incidence of certain chronic diseases, including smoking, as well as the effectiveness of cytisinicline. This protocol aims to evaluate the efficacy of the synergistic effect of combining structured physical exercise, brief counseling, and cytisinicline administration in achieving smoking cessation. The study will be an experimental, multicenter, randomized, and controlled trial with two parallel arms, conducted by a multidisciplinary team within the primary care setting of the Andalusian public health system, with a 12-month follow-up. The estimated sample size is 75 participants per arm. One of the study arms will include a structured exercise program aligned with the recently approved regional Andalusian health plan.

03

Conditions studied

  • Smoking Cessation

Keywords

  • Tabacco
  • Cytisinicline
  • Exercise
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 65 years.
  • Smoking a minimum of 10 cigarettes per day.
  • In the contemplation or action stage according to Prochaska and DiClemente's Transtheoretical Model.
  • Prepared to initiate smoking cessation treatment imminently and with commitment.
  • Demonstrating a high level of nicotine dependence, with a Fagerström test score of 7 or higher.
  • Exhibiting significant motivation to quit smoking, as indicated by a Richmond test score of 6 or higher.
  • Having made at least one prior attempt to quit smoking within the past year.
  • Enrolled in or covered by the Andalusian Public Health System.

Exclusion criteria

Exclusion Criteria:

  • Individuals with medical conditions that contraindicate participation in physical exercise, including but not limited to malignant hypertension, heart failure, hyperthyroidism, peripheral arterial disease, or other conditions deemed by the research team to pose a risk of adverse events or significantly impair adherence to the study.
  • Individuals who have experienced changes in their usual treatment regimen within the past 90 days.
  • Individuals unable to provide .
  • Individuals with pathological conditions that significantly reduce to less than 5 years.
  • Individuals with as specified in the product information for cytisinicline , such as pregnancy, breastfeeding, to cytisinicline, unstable angina, recent myocardial infarction, arrhythmias, or recent stroke.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Cytisinicline and exercise

    Smokers who will receive directed physical exercise and brief counseling while undergoing treatment according to the care process.

    Drug: Cytisinicline and exercise

  • Active comparator
    Cytisinicline

    Smokers who will receive an informational leaflet and brief counseling when they begin cytisinicline treatment, according to the care process.

    Drug: Cytisinicline

Interventions

  • DrugCytisinicline and exercise

    Drug page: CytisineStudies of CytisineCytisine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Doctors will provide brief, personalized counseling anti-smoking plan. This counseling will support smokers in the determination-action phase of behavior change. Physicians will administer cytisine as follows: 1 tablet every 2 hours (maximum 6 per day) from days 1-3; every 2.5 hours (maximum 5 per day) from days 4-12; every 3 hours (maximum 4 per day) from days 13-16; every 5 hours (maximum 3 per day) from days 17-20; and 1-2 tablets per day (maximum 2 per day) from days 21-25. Participants will follow a combined aerobic and strength exercise program. This includes at least 150 minutes of moderate-intensity aerobic physical activity per week, or 75 minutes of vigorous-intensity aerobic activity, or an equivalent combination of both. Aerobic activity should be performed in sessions lasting at least 10 minutes.

    Also known as: Cytisinicline, Exercise

  • DrugCytisineStudies of CytisineCytisine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Same intervention as the experimental group without directed exercise prescription

06

What researchers measure

Primary outcomes

  1. Smoking

    Number of cigarettes smoked daily.

    Time frame: Day 0; Day 7; Day 30; Day; 60; Day 90; Day 180; Day 365

  2. Smoking cessation

    Dichotomous variable (yes/not) asking in the clinical history.

    Time frame: Day 30; Day; 60; Day 90; Day 180; Day 365

  3. Carbon monoxide exhaled air

    Carbon monoxide in the subject's exhaled air. It will be measured with a Co-oximeter of the brand "Co Check", code 01PLS18B, with a sensitivity of 1 ppm and accuracy (repeatability) of 2%. The unit of measurement of the variable is parts per million (ppm).

    Time frame: Day 0; Day 30; Day; 60; Day 90; Day 180; Day 365

Secondary outcomes

  1. Blood pressure

    Blood pressure is measured in the non-dominant arm three times, with a 5-minute gap between each measurement, using an automatic oscillometer (Omron M3 Intellisense HEM-75051-EV; IOMRON Healthcare Europe) equipped with a child-specific cuff. The average of the three measurements is recorded for both systolic and diastolic blood pressure. The mean blood pressure values are expressed in mmHg.

    Time frame: Day 0; Day 30; Day; 60; Day 90; Day 180; Day 365

  2. Weight

    Weight in grams is measured by the precision weighing scale model Tanita 780PMA.

    Time frame: Day 0; Day 30; Day; 60; Day 90; Day 180; Day 365

  3. Body mass index

    Body mass index in kilograms per square meter is calculated.

    Time frame: Day 0; Day 30; Day; 60; Day 90; Day 180; Day 365

  4. Physical dependence on nicotine

    Physical dependence on nicotine measured by the Fagerström Test for Nicotine Dependence (FTND). This test consists of 6 questions, and each question has response options with assigned scores. The total score is the sum of the response scores and ranges from 0 to 10 points. The scoring scale is interpreted as follows: 0-2 points: Low dependence. 3-4 points: Low to moderate dependence. 5 points: Moderate dependence. 6-7 points: High dependence. 8-10 points: Very high dependence.

    Time frame: Day 0; Day 7; Day 30; Day; 60; Day 90; Day 180; Day 365

  5. Psychological dependence on smoking

    Physical dependence on nicotine measured by the Glover-Nilsson Smoking Behavioral Questionnaire (GN-SBQ). The GN-SBQ consists of 11 questions, each with response options ranging from 0 (never) to 4 (always), forming a 5-point Likert scale. The total test score is obtained by summing the responses to all the questions, resulting in a possible score range of 0 to 44 points. The scores are interpreted as follows: 0-10 points: Low behavioral dependence on tobacco. 11-22 points: Moderate behavioral dependence. 23-33 points: High behavioral dependence. 34-44 points: Very high behavioral dependence.

    Time frame: Day 0; Day 7; Day 30; Day; 60; Day 90; Day 180; Day 365

  6. Motivation to quit smoking

    Physical dependence on nicotine measured by the Richmond Smoking Withdrawal Questionnaire. This test consists of 4 questions. Each question has response options with scores ranging from 0 to 3 points. The total score is obtained by summing the responses, resulting in a possible range of 0 to 10 points. The interpretation of the scores is as follows: 0-3 points: Low dependence on nicotine. 4-5 points: Moderate dependence. 6-7 points: High dependence. 8-10 points: Very high dependence.

    Time frame: Day 0; Day 7; Day 30; Day; 60; Day 90; Day 180; Day 365

  7. Alcohol consumption

    Weekly alcohol consumption. Unit of measurement is Standard Drink Units

    Time frame: Day 0; Day 7; Day 30; Day; 60; Day 90; Day 180; Day 365

  8. Physical activity

    Time physical activity performed daily will be measured with the Global Physical Activity Questionnaire (GPAQ) of the World Health Organization (WHO). It collects quantitative information on physical activity in three different domains: 1) Physical activity at work (including occupational activity and domestic work); 2)Transport (physical activity related to transportation, such as walking or cycling); 3) Recreational physical activity (sports, exercise, leisure). For each of these domains, the GPAQ asks respondents about the frequency (days per week) and duration (minutes per day) of the physical activities performed. Additionally, the GPAQ also inquires about the time spent on sedentary activities. The collected information is used to calculate the respondent's level of physical activity, which is categorized into levels such as low, moderate, or high physical activity according to WHO guidelines.

    Time frame: Day 0; Day 7; Day 30; Day; 60; Day 90; Day 180; Day 365

  9. Self-efficacy for physical activity

    Self-efficacy for physical activity measured by the Benisovich Test. The scale used in this test is an 11-point Likert scale, ranging from 0 to 10, where: 0 indicates "not confident at all" or "I have no confidence at all that I could do this." 10 indicates "completely confident" or "I have complete confidence that I could do this."

    Time frame: Day 0; Day 7; Day 30; Day; 60; Day 90; Day 180; Day 365

  10. Heart rate in rest

    The unit of measure is beats per minute (bpm).

    Time frame: Day 0; Day 7; Day 30; Day; 60; Day 90; Day 180; Day 365

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Dec 2025, 11 months later.

Of 53 non-industry phase 4 interventional studies under Smoking Cessation, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 11 months is below that.

Counting every sponsor, half of 56 studies reached it within 35 months; a quarter within 21 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2024
First posted
Aug 30, 2024
StartEst.
Jan 1, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Sep 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06579846
Lead sponsor
Maimónides Biomedical Research Institute of Córdoba
Collaborators
Universidad de Córdoba
Responsible party
Sponsor
First posted
Aug 30, 2024
Start date
Jan 1, 2025 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Sep 4, 2024

Study contacts

Antonio Ranchal Sanchez, MD, PhD
Contact
en1rasaa@uco.es
+34957213700

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cytisine

Start the discussion